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ABSTRACT
Oncogenic osteomalacia is a rare acquired paraneoplastic syndrome caused by excessive renal phosphate wast-
ing that causes hypophosphatemia and osteomalacia. Fibroblast growth factor 23 (FGF23) has been identified as 
the causative factor of oncogenic osteomalacia and is also known as its diagnostic marker in immunohistochem-
istry studies. Recently, the authors of the present study experienced a female patient with a prolonged history of 
osteomalacia; a rare maxillary sinus tumor was confirmed by anti-FGF23 immunohistochemical staining as the 
causative tumor. The present case is the first reported case in Korea to have been diagnosed as a head and neck 
tumor associated with oncogenic osteomalacia according to anti-FGF23 immunohistochemical staining.
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INTRODUCTION
Oncogenic osteomalacia or tumor-induced osteomala-
cia is a rare acquired paraneoplastic syndrome character-
ized by hypophosphatemia due to renal phosphate wast-
ing. Its clinical features include adult-onset bone pain, 
atrophy of proximal muscles, gait disturbance, and mul-
tiple bone fractures. Due to the slow-growing nature and 
absence of localized symptoms of the associated tumor, 
it takes an average of five years from the time of clini-
cal presentation to diagnosis of the disease.1) Recently, fi-
broblast growth factor 23 (FGF23) has been identified as 
the causative factor of oncogenic osteomalacia in several 
studies.2) 3) FGF23, which belongs to the FGF subfamily, 
plays a major role in phosphate homeostasis, and its over-
expression seems to cause hypophosphatemic conditions. 
In this case, we report a female patient with prolonged 
history of osteomalacia with a rare maxillary sinus tumor 
that was confirmed as the causative tumor by FGF23 im-
munohistochemical staining. The present case is the first 
reported case in Korea to have been diagnosed by FGF23 
immunohistochemical staining as a head & neck tumor 
associated with oncogenic osteomalacia.
CASE
A 58-year-old female patient was referred to the De-
partment of Otorhinolaryngology because of a bony lesion 
at the right maxilla in bone scan (Fig. 1A) and a mass 
lesion on the posterior wall of the right maxillary sinus 
in positron-emission tomography computerized tomog-
raphy (PET-CT) (Fig. 1B). She suffered from multiple 
pathologic fractures on both legs and osteomalacia with 
high serum alkaline phosphate, severe hypophosphatemia, 
and slightly low 1,25-dihydroxy vitamin D3. She had no 
nasal symptoms or trismus. Clinical examination with a 
nasal endoscope revealed no remarkable findings. Para-
nasal sinus CT & magnetic resonance imaging (MRI) de-
tected a mass lesion on the postero-inferior wall of the 
right maxillary sinus, which correlated with her PET-CT 
and bone scan findings. The 1.5x1.5x2 cm-sized mass was 
expanding to the right pterygopalatine fossa, which was 
well-enhanced on a T1-weighted gadolinium-enhanced 
view (Fig. 1C, D).
Biopsy of tumor via a sublabial approach was per-
formed. The anterior wall of the right maxillary sinus was 
punctured, and the mass was observed on the postero-in-
ferior portion. It bled easily and was friable. Curettage and 
piecemeal resection was performed (Fig. 2). Histologic ex-
amination revealed proliferation of spindle cells with dark 
and uniform nuclei, and proliferation of the capillary ves-
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Fig. 1. A. Whole body bone 
scan showing multiple 
pathologic fracture foci. 
Notice the bony lesion on 
the right maxilla (arrow). B. 
PET-CT illustrating focal FDG 
uptake on the posterior wall 
of the right maxillary sinus 
(arrow). C. PNS CT showing 
a mass lesion on the poste-
ro-inferior wall of the right 
maxillary sinus (arrow). D. 
Sagittal MRI (T1 gadolinium-
enhanced view) illustrat-
ing well-enhanced lesion 
on the right maxillary sinus 
expanding to the pterygo-
palatine fossa.
Fig. 2. A. Intraoperative pho-
to showing the mass on the 
posteroinferior portion of 
the right maxillary sinus (ar-
row). B. The same portion 
of the right maxillary sinus is 







sels (Fig. 3A). Immunohistochemical staining for CD34, 
CD31, HHV-8, desmin, SMA, and S-100 was performed. 
Tumor cells were positive for CD34, CD31, and negative 
for HHV-8, desmin, SMA, and S-100, which supported 
a diagnosis of spindle cell hemangioma. Immunohis-
tochemical staining for FGF23 using monoclonal antibody 
(Enzo Life Sciences International, Inc., Farmingdale, NY) 
was also performed, and the cytoplasm of tumor cells was 
clearly positive, which confirmed the pathologic diagnosis 
of oncogenic osteomalacia (Fig. 3B).
The serum phosphate level slightly increased at 2 
months post-operation. We warned the patient about the 
possibility of remnant tumors, and recommended revision 
of the surgery (e.g. maxillectomy including pterygopala-
tine fossa), but she refused angiography and surgery, and 
failed to follow-up.
DISCUSSION
Oncogenic osteomalacia is a rare acquired paraneo-
plastic syndrome caused by excessive renal phosphate 
wasting. Renal phosphate wasting is an important mech-
anism for developing osteomalacia. Less than 100 cases 
of oncogenic osteomalacia have been reported world-
wide. Laboratory findings show characteristically pro-
found hypophosphatemia and hyperphosphaturia with 
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reduced or inappropriately normal 1, 25-dihydroxyvi-
tamin D. Serum alkaline phosphate levels are elevated, 
along with normal serum calcium and PTH level. In this 
case, the patient showed low preoperative serum phos-
phate and low 1, 25-dihydroxyvitamin D with elevated 
alkaline phosphatase.4) 5)
Oncogenic osteomalacia in the maxillary sinus is 
very limited. Only eight cases of oncogenic osteomala-
cia involving the maxillary sinus have been reported in 
the published literature in English, including the present 
case.6-9) Patients were aged 35-75 with a mean age of 46. 
Oncogenic osteomalacia is known to affect people in their 
30s without preponderance of either gender.10) Among the 
maxillary sinus origin oncogenic osteomalacia patients, 
two were male and six were female. Because of the slow-
growing nature of the associated tumor, the average time 
taken from clinical presentation to identification of the 
tumor was five years. The associated tumor was hard to 
identify in the current case because it was small and slow-
growing. There was no clinical presentation involving the 
maxilla-facial area of the patient, hence head & neck im-
aging was not performed until its appearance on the PET-
CT. It was located at the posterior wall of right maxillary 
sinus expanding to the pterygopalatine fossa. This case 
suggests the need for a thorough head & neck examination 
of patients with suspected oncogenic osteomalacia. 
Recently, FGF23 has been identified as the causative 
factor of oncogenic osteomalacia and X-linked hypo-
phosphatemia in several studies.2) 3) In the present case, we 
found that the tumor was positive for FGF23, which repre-
sents that it was associated with oncogenic osteomalacia. 
The present case is the first reported case in Korea that 
was diagnosed by FGF23 immunohistochemical staining 
as oncogenic osteomalacia associated with a head & neck 
tumor. Measurement of serum FGF23 levels can be also 
useful in the diagnosis and identification of the tumor as-
sociated with oncogenic osteomalacia.11)
To treat the tumor, we first performed piecemeal resec-
tion and biopsy because the mass was well-enhanced on 
MRI. We also planned a maxillectomy after pathologic 
confirmation and angiography. However, the patient re-
fused further evaluation and treatment. Piecemeal remov-
al of tumor caused the serum phosphate level to be elevat-
ed, but the serum phosphate level was not restored to its 
normal level. The possible mechanism of elevated serum 
phosphate can be explained as follows; hyperphosphatu-
ria decreases as serum FGF 23 level is decreased by the 
removal of tumor, which in turn causes increase of serum 
phosphate level. Thus, a radical operation was necessary 
for complete cure of the disease.
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